Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBIn an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Recent Approvals Signal a Bright Future for Myelodysplastic …
WEBDec 22, 2023 · Ivosidenib . In October 2023, ivosidenib (Tibsovo) was cleared by the FDA for the treatment of IDH1-mutated relapsed or refractory MDS, based on findings from the AG120-C-001 trial (NCT02074839).4 In the study, 18 adult patients with relapsed or refractory MDS with an IDH1 mutation received oral ivosidenib daily on a 28-day cycle. All responses in the trial were complete responses (CRs), and ...
10 Years in CLL: Top Advances From 2012-2022 - Targeted Oncology
WEBApr 14, 2022 · Targeted therapies have brought about an increased life expectancy for many individuals with a CLL diagnosis. “In the past, the ‘chronic’ in CLL meant you could live 10 years,” Davids said. “Today, the goal for many patients is to live out a normal life span and not die from CLL.”. But there remain the unmet needs of patients who do ...
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Managing Chemotherapy Toxicities for Improved Patient Outcomes
WEBMar 29, 2021 · In a large majority of patients, even when treating with chemotherapy that is highly emetogenic, nausea and vomiting can be prevented. Options include 5-HT3 receptor antagonists (such as ondansetron), NK-1 receptor antagonists (such as aprepitant), glucocorticoids (such as dexamethasone), and olanzapine, a …
Diagnosing and Treating NET-Related Diarrhea - Targeted Oncology
WEBOct 21, 2017 · A review of the patient’s diet, medications, family history, and a physical exam are also helpful. Testing of diarrhea in patients without NETs often include inflammatory markers and testing for Celiac disease. Tests of the patients’ stool can test for fecal fat, electrolytes, and more. Endoscopic and breath tests can also help in looking ...
The Journal of Targeted Therapies in Cancer - Targeted Oncology
WEBThe Journal of Targeted Therapies in Cancer. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Addition of Polatuzumab to R-CHOP Improves Outcomes for …
WEBJan 10, 2023 · The phase 3 POLARIX study (NCT03274492) elicited superior progression-free survival (PFS) and a similar safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) administered polatuzumab vedotin (Polivy), rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).
Diagnosis, Staging, and Testing for Nonsquamous NSCLC
WEBNov 21, 2017 · 1 NSCLC originates from lung epithelial cells of the central bronchi to terminal alveoli, 2 nonsquamous NSCLC will generally originate in peripheral lung tissue, and squamous cell carcinoma (SCC) primarily originates near a central bronchus.. Lung cancer, including both NSCLC and SCLC, contributes to the most cancer-related deaths in the United States, with 155,870 deaths estimated for 2017. 2 ...
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
WEBJan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers ...
Skip to content